Clinical data | |
---|---|
Trade names | Permax, Prascend (veterinary), others |
Other names | 8β-[(Methylthio)methyl]-6-propylergoline |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 90% |
Metabolism | Extensively Hepatic |
Elimination half-life | 27 hours |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.241.322 |
Chemical and physical data | |
Formula | C19H26N2S |
Molar mass | 314.49 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Pergolide, sold under the brand name Permax and Prascend (veterinary) among others, is an ergoline-based dopamine receptor agonist used in some countries for the treatment of Parkinson's disease. Parkinson's disease is associated with reduced dopamine synthesis in the substantia nigra of the brain. Pergolide acts on many of the same receptors as dopamine to increase receptor activity.
It was patented in 1978[3] and approved for medical use in 1989.[4] In 2007, pergolide was withdrawn from the U.S. market for human use after several published studies revealed a link between the drug and increased rates of valvular heart disease.[5] However, a veterinary form of pergolide, marketed under the trade name Prascend, is permitted for the treatment of pituitary pars intermedia dysfunction (PPID) also known as equine Cushing's syndrome (ECS) in horses.[6]
{{cite web}}
: CS1 maint: bot: original URL status unknown (link)